1 recruiting, 1 unknown. .
Follow Ze-yang Ding, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma drug eluting beads-transcatheter arterial chemoembolization, envatinib plus anti-PD(L)1 - Cholangiocarcinoma Non-resectable | Unknown | Ze-yang Ding, MD | 100 | 2022-02-01 | 2024-01-09 | |
| Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma HAIC, Bevacizumab plus Atezolizumab, Bevacizumab Biosimilar IBI305 plus sintilimab - Hepatocellular Carcinoma Non-resectable | Recruiting | Ze-yang Ding, MD | 300 | 2020-05-19 | 2025-03-25 |
Carcinoma, Hepatocellular (1) · Cholangiocarcinoma (1) · Liver Neoplasms (1)
Bevacizumab (1) · Glutamyl Aminopeptidase (1) · Immune Checkpoint Inhibitors (1) · Sorafenib (1) · apatinib (1) · atezolizumab (1) · camrelizumab (1) · donafenib (1) · lenvatinib (1) · regorafenib (1) · sintilimab (1) · spartalizumab (1)
China (2)
Wanguang Zhang, M.D. (1) · Ze-yang Ding, M.D. (1)